Together, MZT2B is consistently upregulated in NSCLC that correlates with adverse clinicopathological features and poor prognosis and critically regulates mitochondrial function and promotes NSCLC progression, in part, by promoting COX5B expression. This evidence concerns the gene COX5B and non-small cell lung carcinoma.